CORDIS - Risultati della ricerca dell’UE
CORDIS

Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions

Descrizione del progetto

Identificare i motivi della risposta negativa dei pazienti al trattamento

L’identificazione dei meccanismi molecolari che possono influenzare positivamente o negativamente la risposta di un paziente alle cure mediche è una questione chiave tra gli operatori sanitari. Uno studio promosso da 3TR, un consorzio di istituzioni universitarie, PMI e aziende farmaceutiche leader, affronterà questo problema. Il progetto, finanziato dall’UE, applicherà bioinformatica e metodi di controllo per raccogliere e analizzare dati provenienti da sangue, tessuti e altri fluidi durante l’intero processo di trattamento. Creerà inoltre una piattaforma di dati centralizzata per una migliore gestione e implementerà un quadro molecolare e clinico inclusivo dei pazienti con patologie simili. Il progetto intende spiegare il ruolo che il nostro microbioma, la genetica e la genomica regolativa svolgono durante il trattamento.

Obiettivo

3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The molecular identification of groups of patients to whom a drug will benefit, will allow focusing on those who are drug orphan. Harmonization of data from existing academy or industry-sponsored studies will identify biomarkers to inform a new collection. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a de novo observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Because the studies will be at different phases of progression, a carrousel model of work was designed for input and output of data to be continuously analysed, and interpreted, to inform those measurements to be undertaken and allow cross-validation of results. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression. The working aims of 3TR are: 1) establish a centralized data management platform; 2) perform comprehensive molecular and clinical characterisation of a prospective patient cohort; 3) establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods; 4) identify sets of predictive biomarkers of response/non-response to therapies; 5) improve the competitiveness of European industry and support development of novel solutions. 3TR will sustain beyond the project end the samples and its knowledge base. 3TR will challenge and revolutionize the conventional single-disease based approach with important implications in future disease treatment.

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.
Contribution nette de l'UE
€ 9 468 779,68
Indirizzo
AVENIDA AMERICO VESPUCIO 15 EDIF S2
41092 Sevilla
Spagna

Mostra sulla mappa

Regione
Sur Andalucía Sevilla
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 9 579 779,68

Partecipanti (86)